vs
亚玛芬体育（AS）与Insulet Corporation（PODD）财务数据对比。点击上方公司名可切换其他公司
亚玛芬体育的季度营收约是Insulet Corporation的1.3倍（$1.1B vs $783.7M），Insulet Corporation净利率更高（13.0% vs 1.8%，领先11.2%），亚玛芬体育自由现金流更多（$92.2M vs $48.2M）
亚玛芬体育是芬兰跨国运动装备企业，总部位于赫尔辛基，成立于1950年。早年为涉足烟草贸易、航运、出版等领域的多元化工业集团，后逐步转型专注于体育用品的生产与营销，现有员工超9700人，2018年起成为中国安踏体育旗下子公司。
Insulet Corporation是深耕糖尿病治疗领域的医疗器械企业，核心产品为胰岛素泵，通过持续皮下输注胰岛素的疗法为患者给药。其产品通常由泵主体、一次性胰岛素储药仓，以及包含皮下植入套管和连接管路的一次性输注套件构成，满足不同患者的治疗需求。
AS vs PODD — 直观对比
营收规模更大
AS
是对方的1.3倍
$783.7M
净利率更高
PODD
高出11.2%
1.8%
自由现金流更多
AS
多$44.0M
$48.2M
损益表 — Q1 FY2024 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.1B | $783.7M |
| 净利润 | $19.0M | $101.6M |
| 毛利率 | 52.8% | 72.6% |
| 营业利润率 | 12.4% | 18.7% |
| 净利率 | 1.8% | 13.0% |
| 营收同比 | — | 31.2% |
| 净利润同比 | — | 0.9% |
| 每股收益（稀释后） | $0.05 | $1.42 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASPODD
| Q4 25 | — | $783.7M | ||
| Q3 25 | — | $706.3M | ||
| Q2 25 | — | $649.1M | ||
| Q1 25 | — | $569.0M | ||
| Q4 24 | — | $597.5M | ||
| Q3 24 | — | $543.9M | ||
| Q2 24 | — | $488.5M | ||
| Q1 24 | $1.1B | $441.7M |
净利润ASPODD
| Q4 25 | — | $101.6M | ||
| Q3 25 | — | $87.6M | ||
| Q2 25 | — | $22.5M | ||
| Q1 25 | — | $35.4M | ||
| Q4 24 | — | $100.7M | ||
| Q3 24 | — | $77.5M | ||
| Q2 24 | — | $188.6M | ||
| Q1 24 | $19.0M | $51.5M |
毛利率ASPODD
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% | ||
| Q1 24 | 52.8% | 69.5% |
营业利润率ASPODD
| Q4 25 | — | 18.7% | ||
| Q3 25 | — | 16.7% | ||
| Q2 25 | — | 18.7% | ||
| Q1 25 | — | 15.6% | ||
| Q4 24 | — | 18.3% | ||
| Q3 24 | — | 16.2% | ||
| Q2 24 | — | 11.2% | ||
| Q1 24 | 12.4% | 12.9% |
净利率ASPODD
| Q4 25 | — | 13.0% | ||
| Q3 25 | — | 12.4% | ||
| Q2 25 | — | 3.5% | ||
| Q1 25 | — | 6.2% | ||
| Q4 24 | — | 16.9% | ||
| Q3 24 | — | 14.2% | ||
| Q2 24 | — | 38.6% | ||
| Q1 24 | 1.8% | 11.7% |
每股收益（稀释后）ASPODD
| Q4 25 | — | $1.42 | ||
| Q3 25 | — | $1.24 | ||
| Q2 25 | — | $0.32 | ||
| Q1 25 | — | $0.50 | ||
| Q4 24 | — | $1.38 | ||
| Q3 24 | — | $1.08 | ||
| Q2 24 | — | $2.59 | ||
| Q1 24 | $0.05 | $0.73 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | — |
| 总债务越低越好 | — | $930.8M |
| 股东权益账面价值 | — | $1.5B |
| 总资产 | — | $3.2B |
| 负债/权益比越低杠杆越低 | — | 0.61× |
8季度趋势，按日历期对齐
总债务ASPODD
| Q4 25 | — | $930.8M | ||
| Q3 25 | — | $934.9M | ||
| Q2 25 | — | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B | ||
| Q1 24 | — | $1.4B |
股东权益ASPODD
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.3B | ||
| Q4 24 | — | $1.2B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $998.4M | ||
| Q1 24 | — | $790.7M |
总资产ASPODD
| Q4 25 | — | $3.2B | ||
| Q3 25 | — | $3.0B | ||
| Q2 25 | — | $3.5B | ||
| Q1 25 | — | $3.5B | ||
| Q4 24 | — | $3.1B | ||
| Q3 24 | — | $3.0B | ||
| Q2 24 | — | $2.9B | ||
| Q1 24 | — | $2.6B |
负债/权益比ASPODD
| Q4 25 | — | 0.61× | ||
| Q3 25 | — | 0.68× | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | — | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× | ||
| Q1 24 | — | 1.72× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $114.3M | $183.3M |
| 自由现金流经营现金流 - 资本支出 | $92.2M | $48.2M |
| 自由现金流率自由现金流/营收 | 8.8% | 6.2% |
| 资本支出强度资本支出/营收 | 2.1% | 17.2% |
| 现金转化率经营现金流/净利润 | 6.02× | 1.80× |
| 过去12个月自由现金流最近4个季度 | — | $377.7M |
8季度趋势，按日历期对齐
经营现金流ASPODD
| Q4 25 | — | $183.3M | ||
| Q3 25 | — | $125.7M | ||
| Q2 25 | — | $196.5M | ||
| Q1 25 | — | $63.8M | ||
| Q4 24 | — | $147.7M | ||
| Q3 24 | — | $98.5M | ||
| Q2 24 | — | $96.5M | ||
| Q1 24 | $114.3M | $87.6M |
自由现金流ASPODD
| Q4 25 | — | $48.2M | ||
| Q3 25 | — | $100.1M | ||
| Q2 25 | — | $177.9M | ||
| Q1 25 | — | $51.5M | ||
| Q4 24 | — | $94.1M | ||
| Q3 24 | — | $71.8M | ||
| Q2 24 | — | $74.0M | ||
| Q1 24 | $92.2M | $65.5M |
自由现金流率ASPODD
| Q4 25 | — | 6.2% | ||
| Q3 25 | — | 14.2% | ||
| Q2 25 | — | 27.4% | ||
| Q1 25 | — | 9.1% | ||
| Q4 24 | — | 15.7% | ||
| Q3 24 | — | 13.2% | ||
| Q2 24 | — | 15.1% | ||
| Q1 24 | 8.8% | 14.8% |
资本支出强度ASPODD
| Q4 25 | — | 17.2% | ||
| Q3 25 | — | 3.6% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 2.2% | ||
| Q4 24 | — | 9.0% | ||
| Q3 24 | — | 4.9% | ||
| Q2 24 | — | 4.6% | ||
| Q1 24 | 2.1% | 5.0% |
现金转化率ASPODD
| Q4 25 | — | 1.80× | ||
| Q3 25 | — | 1.43× | ||
| Q2 25 | — | 8.73× | ||
| Q1 25 | — | 1.80× | ||
| Q4 24 | — | 1.47× | ||
| Q3 24 | — | 1.27× | ||
| Q2 24 | — | 0.51× | ||
| Q1 24 | 6.02× | 1.70× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AS
| Americas2 | $409.6M | 39% |
| EMEA1 | $356.9M | 34% |
| Greater China3 | $205.6M | 20% |
| Asia Pacific4 | $78.2M | 7% |
PODD
| U.S.Omnipod | $567.8M | 72% |
| International Omnipod | $214.0M | 27% |
| Drug Delivery | $1.9M | 0% |
